首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Effect of cyclic GMP-dependent vasodilators on the expression of inducible nitric oxide synthase in vascular smooth muscle cells: role of cyclic AMP.
【2h】

Effect of cyclic GMP-dependent vasodilators on the expression of inducible nitric oxide synthase in vascular smooth muscle cells: role of cyclic AMP.

机译:循环GMP依赖性血管扩张剂对血管平滑肌细胞中可诱导型一氧化氮合酶表达的影响:循环AMP的作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. In the present study we examined whether interleukin-1 beta (IL-1 beta) increases the activity of adenylyl cyclase in vascular smooth muscle cells and determined its role in the cytokine-induced expression of the inducible nitric oxide synthase (iNOS) and activation of nuclear transcription factor-kappa B (NF-kappa B). In addition the interaction between cyclic AMP- and cyclic GMP-elevating agonists on the IL-1 beta-stimulated expression of iNOS was examined. 2. Exposure of vascular smooth muscle cells to IL-1 beta stimulated the formation of cyclic AMP but not of cyclic GMP. The intracellular level of cyclic AMP reached a maximum within 1 h and then gradually declined over the next 5 h. This IL-1 beta (60 u ml-1)-stimulated formation of cyclic AMP was modest (about 3 fold at 60 u ml-1 for 1 h) compared to that evoked by isoprenaline (about 9 fold at 3 x 10(-6) M for 2 min). 3. The IL-1 beta (60 u ml-1 for 24 h)-stimulated accumulation of nitrite, which was taken as an index of NO production, was concentration-dependently increased by preferential inhibitors of cyclic AMP-dependent phosphodiesterases (rolipram and trequinsin). This effect was reproduced by a specific activator of the cyclic AMP-dependent protein kinase(s) A, Sp-8-CPT-cAMPS (10(-4) M) but was prevented by a specific inhibitor of cyclic AMP-dependent protein kinase(s) A, Rp-8-CPT-cAMPS (10(-4) M). These compounds alone [rolipram (10(-6) M), trequinsin (3 x 10(-6) M) and Sp-8-CPT-cAMPS (10(-4) M)] slightly but significantly increased the release of nitric oxide while Rp-8-CPT-cAMPS elicited no such effect. 4. Inducible NOS protein was expressed in IL-1 beta (30 u ml-1, 24 h)-stimulated smooth muscle cells as assessed by Western blot analysis. The level of iNOS protein was markedly increased in smooth muscle cells which had been exposed to IL-1 beta in combination with either rolipram (3 x 10(-6) M) or Sp-8-CPT-cAMPS (10(-4) M) but was reduced in those exposed to IL-1 beta and Rp-8-CPT-cAMPS (10(-4) M). A weak expression of iNOS protein was found in smooth muscle cells which had been exposed to either Sp-8-CPT-cAMPS or rolipram alone for 24 h while Rp-8-CPT-cAMPS elicited no such effect. 5. Exposure of smooth muscle cells to IL-1 beta (30 u ml-1) for 30 min increased the level of NF-kappa B-DNA complexes in nuclear extracts as detected by electrophoretic mobility shift assay. Similar levels of NF-kappa B-DNA complexes were found in cells which had been exposed to IL-1 beta in combination with either Sp-8-CPT-cAMPS (10(-4) M), trequinsin (10(-6) M) or rolipram (10(-6) M). None of the modulators alone affected the basal level of NF-kappa B binding activity. 6. NO-donors [sodium nitroprusside (SNP) 10(-4) M; dinitrosyl-iron-di-L-cysteine-complex (DNIC), 10(-4) M; 3-morpholino-sydnonimine (SIN-1), 10(-4) M] and atrial natriuretic factor (10(-6) M) significantly increased the IL-1 beta (30 or 60 u ml-1, 24 h)-stimulated expression of iNOS protein and activity as assessed indirectly by the conversion of oxyhaemoglobin to methaemoglobin. In the absence of IL-1 beta, SNP (10(-4) M, 24 h) but not the other cyclic GMP-dependent vasodilators caused a modest expression of iNOS protein. No such effect was found in smooth muscle cells exposed to SNP in combination with Rp-8-CPT-cAMPS (10(-4) M) while an increased level of iNOS protein was found in those exposed to SNP in combination with either Sp-8-CPT-cAMPS (10(-4) M) or rolipram (3 x 10(-6) M). 7. Exposure of vascular smooth muscle cells to either S-nitroso-L-cysteine (Cys-SNO, 10(-4) M), SNP (10(-4) M) or SIN-1 (10(-4) M) for 35 min affected minimally the basal activation of NF-kappa B but abolished that evoked by IL-1 beta (30 u ml-1 added during the last 30 min). However, addition of Cys-SNO following the stimulation with IL-1 beta (during the last 5 min of the 30 min exposure period) reduced the level of NF-kappa B-DNA complexes only slightly. 8. These data indicate that the cyclic AMP-dependent pathway plays a decisi
机译:1.在本研究中,我们检查了白介素-1 beta(IL-1 beta)是否增加了血管平滑肌细胞中腺苷酸环化酶的活性,并确定了其在细胞因子诱导的可诱导型一氧化氮合酶(iNOS)和核转录因子-κB(NF-κB)的活化。此外,还检查了环AMP和环GMP升高激动剂对IL-1β刺激的iNOS表达的相互作用。 2.将血管平滑肌细胞暴露于IL-1β刺激了环AMP的形成,但不刺激环GMP的形成。细胞内环状AMP的水平在1小时内达到最大值,然后在接下来的5小时内逐渐下降。与由异丙肾上腺素引起的(在3 x 10(- 6)M 2分钟)。 3. IL-1β(60 u ml-1持续24 h)刺激的亚硝酸盐积累(被视为NO产生的指标)被环状AMP依赖性磷酸二酯酶的优先抑制剂(咯利普兰和trequinsin)。此效应由环状AMP依赖性蛋白激酶A的特异性激活剂Sp-8-CPT-cAMPS(10(-4)M)再现,但由环状AMP依赖性蛋白激酶的特异性抑制剂阻止(s)A,Rp-8-CPT-cAMPS(10(-4)M)。单独使用这些化合物[咯利普兰(10(-6)M),trequinsin(3 x 10(-6)M)和Sp-8-CPT-cAMPS(10(-4)M)]略微增加了硝酸的释放Rp-8-CPT-cAMPS不会引起这种作用。 4.如通过蛋白质印迹分析所评估的,诱导型NOS蛋白在IL-1β(30uml-1,24h)刺激的平滑肌细胞中表达。在暴露于IL-1 beta并与咯利普兰(3 x 10(-6)M)或Sp-8-CPT-cAMPS(10(-4)结合使用)的平滑肌细胞中,iNOS蛋白的水平显着增加。 M),但在暴露于IL-1 beta和Rp-8-CPT-cAMPS的人群中降低(10(-4)M)。在仅暴露于Sp-8-CPT-cAMPS或咯利普兰24小时的平滑肌细胞中发现iNOS蛋白表达较弱,而Rp-8-CPT-cAMPS则未引起这种作用。 5.如通过电泳迁移率变动分析所检测,将平滑肌细胞暴露于IL-1 beta(30 u ml-1)30分钟可增加核提取物中NF-κB-DNA复合物的水平。在与Sp-8-CPT-cAMPS(10(-4)M),trequinsin(10(-6))结合暴露于IL-1 beta的细胞中发现了相似水平的NF-κB-DNA复合物M)或咯利普兰(10(-6)M)。单独的调节剂均不影响NF-κB结合活性的基础水平。 6. NO供体[硝普钠(SNP)10(-4)M;二亚硝基-铁-二-L-半胱氨酸复合物(DNIC),10(-4)M; 3-morpholino-sydnonimine(SIN-1),10(-4)M]和心钠素(10(-6)M)显着增加IL-1 beta(30或60 u ml-1,24小时)-氧合血红蛋白转化为血红蛋白间接评估iNOS蛋白的刺激表达和活性。在没有IL-1β的情况下,SNP(10(-4)M,24 h)但不是其他环状GMP依赖性血管扩张剂引起iNOS蛋白的适度表达。在与Rp-8-CPT-cAMPS(10(-4)M)联合使用SNP的平滑肌细胞中未发现这种作用,而在与Sp联合使用SNP的平滑肌细胞中发现iNOS蛋白水平升高。 8-CPT-cAMPS(10(-4)M)或咯利普兰(3 x 10(-6)M)。 7.血管平滑肌细胞暴露于S-亚硝基-L-半胱氨酸(Cys-SNO,10(-4)M),SNP(10(-4)M)或SIN-1(10(-4)M )持续35分钟,对NF-κB的基础活化影响最小,但取消了由IL-1 beta引起的活化(在最后30分钟内添加了30 u ml-1)。但是,在用IL-1 beta刺激后(在30分钟暴露时间的最后5分钟内)添加Cys-SNO只会稍微降低NF-κB-DNA复合物的水平。 8.这些数据表明循环AMP依赖性途径起决定作用

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号